Author

Sperling M Gail

OpenAlex ID: A5028077572

Accrual Barriers and Detection of Early Toxicity Signal in Older Less-Fit Patients Treated with Azacitidine and Nivolumab for Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) in the SWOG 1612 Platform Randomized Phase II/III Clinical Trial

2019 · Annette E. Hay, Sarit Assouline, et al. · Blood · 8

Works count: 1

Citation count: 8

H-index: 1

I10-index: